Name: Dipak Datta, PhD
Senior Principal Scientist, Professor & Head
Cancer Biology Division
CSIR - Central Drug Research Institute & AcSIR
Life Science South Block, Lab # 006
B.S. 10/1, Sector-10, Jankipuram Extension
Sitapur Road, Lucknow-226031, INDIA
Email: dipak.datta@cdri.res.in, dipakdatt@gmail.com
Phone: +91 522 2772450 x4347/48, +91 8756074507(M), Fax: +91 522 2623405

Position and Employment:
06/2019- Present: Head of Division, Cancer Biology, CSIR- Central Drug Research Institute, Lucknow, India.
06/2020- Present: Senior Principal Scientist/ Sc-F, CSIR- Central Drug Research Institute, Lucknow, India.
06/2015- 06/2020: Principal Scientist/Sc-EII, CSIR- Central Drug Research Institute, Lucknow, India.
06/2011- 06/2015: Senior Scientist/Sc-EI, CSIR- Central Drug Research Institute, Lucknow, India.
07/2010-05/2011: Instructor; Harvard Medical School, Boston, USA
09/2004-06/2010: Postdoctoral Research Fellow; CHB & Harvard Medical School, Boston, USA
06/1998-05/2004: Ph.D. (Cancer Biology); CNCI (Jadavpur University), Calcutta, India.

Highlight of Research Activities:

Original Peer Reviewed Article: **61 (Corresponding Author: 16, First Author: 6)**
Patent Filed: **5 (4 as a major contributor)**
Conference Proceedings: **30**
Book Chapter: **4**
PhD Thesis Supervised: **6**
PhD Students currently working: **5**
Research Associate: **1**
Project Assistant: **1**
Google Scholar citations: 2584, h-Index: 29, i-10 index: 52
ORCID ID: (0000-0001-7540-8543)

Complete List of Peer Reviewed Research Publications (*Corresponding Author):

1. K.K. Saini, P. Chaturvedi, A. Sinha, M.P. Singh, M.A. Khan, A. Verma, M.A. Nengroo, S.R. Satrusal, S. Meena, A. Singh, S. Srivastava, J. Sarkar, **D. Datta***, Loss of PERK function promotes ferroptosis by downregulating SLC7A11 (System Xc^-) in colorectal cancer, ***Redox Biology,*** 65, (2023) 102833. **(JIF:11.4)**

2. M. Chakravarti, S. Dhar, S. Bera, A. Sinha, K. Roy, A. Sarkar, S. Dasgupta, A. Bhuniya, A. Saha, J. Das, S. Banerjee, M. Vernekar, C. Pal, N. Alam, **D. Datta**, R. Baral, A. Bose, Terminally exhausted CD8+ T cells resistant to PD-1 blockade promote generation and maintenance of aggressive cancer stem cells, ***Cancer Res***, 83 (2023). **(JIF:13.64)**

3. M. Maheshwari, N. Yadav, M. Hasanain, P. Pandey, R. Sahai, K. Choyal, A. Singh, M.A. Nengroo, K.K. Saini, D. Kumar, K. Mitra, **D. Datta**, J. Sarkar, Inhibition of p21 activates Akt kinase to trigger ROS-induced autophagy and impacts on tumor growth rate, ***Cell Death Dis***, 13 (2022) 1045. **(JIF:9.68)**

4. A. Verma, A. Singh, M.P. Singh, M.A. Nengroo, K.K. Saini, S.R. Satrusal, M.A. Khan, P. Chaturvedi, A. Sinha, S. Meena, A.K. Singh, **D. Datta***, EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis, ***Nat Commun***, 13 (2022) 7344. **(JIF:17.69)**

5. M.A. Nengroo, M.A. Khan, A. Verma, **D. Datta***, Demystifying the CXCR4 conundrum in cancer biology: Beyond the surface signaling paradigm, Biochim ***Biophys Acta Rev Cancer***, 1877 (2022) 188790. **(JIF:11.4)**

6. M.A. Nengroo, A. Verma, **D. Datta***, Cytokine chemokine network in tumor microenvironment: Impact on CSC properties and therapeutic applications, ***Cytokine***, 156 (2022) 155916. **(JIF:3.8)**

7. R. Saklani, P.K. Yadav, M.A. Nengroo, S.L. Gawali, P.A. Hassan, **D. Datta**, D.P. Mishra, I. Dierking, M.K. Chourasia, An Injectable In Situ Depot-Forming Lipidic Lyotropic Liquid Crystal System for Localized Intratumoral Drug Delivery, ***Mol Pharm***, 19 (2022) 831-842. **(JIF:4.9)**

8. A. Mahajan, A. Singh, **D. Datta**, D.S. Katti, Bioinspired Injectable Hydrogels Dynamically Stiffen and Contract to Promote Mechanosensing-Mediated Chondrogenic Commitment of Stem Cells, ***ACS Appl Mater Interfaces***, 14 (2022) 7531-7550. **(JIF:9.5)**

9. A. Verma, A. Sinha, **D. Datta***, Modulation of DNA/RNA Methylation by Small-Molecule Modulators and Their Implications in Cancer, ***Subcell Biochem***, 100 (2022) 557-579.

10. S. Singh, R. Ali, J. Miyan, V. Singh, S. Meena, M. Hasanain, S. Bhadauria, **D. Datta**, J. Sarkar, W. Haq, Facile synthesis of rapamycin-peptide conjugates as mTOR and Akt inhibitors, ***Org Biomol Chem***, 19 (2021) 4352-4358. **(JIF:3.2)**

11. M.A. Nengroo, S. Maheshwari, A. Singh, A. Verma, R.K. Arya, P. Chaturvedi, K.K. Saini, A.K. Singh, A. Sinha, S. Meena, A. Gupta, A. Mishra, J. Sarkar, **D. Datta***, CXCR4 intracellular protein promotes drug resistance and tumorigenic potential by inversely regulating the expression of Death Receptor 5, ***Cell Death Dis***, 12 (2021) 464. **(JIF:9.68)**

12. A.K. Singh, A. Verma, A. Singh, R.K. Arya, S. Maheshwari, P. Chaturvedi, M.A. Nengroo, K.K. Saini, A.L. Vishwakarma, K. Singh, J. Sarkar, **D. Datta***, Salinomycin inhibits epigenetic modulator EZH2 to enhance death receptors in colon cancer stem cells, ***Epigenetics***, 16 (2021) 144-161. **(JIF:4.5)**

13. M. Hasanain, R. Sahai, P. Pandey, M. Maheshwari, K. Choyal, D. Gandhi, A. Singh, K. Singh, K. Mitra, **D. Datta**, J. Sarkar, Microtubule disrupting agent-mediated inhibition of cancer cell growth is associated with blockade of autophagic flux and simultaneous induction of apoptosis, ***Cell Prolif***, 53 (2020) e12749. **(JIF:8.5)**

14. A. Ganesher, P. Chaturvedi, R. Sahai, S. Meena, K. Mitra, **D. Datta***, G. Panda*, New Spisulosine Derivative promotes robust autophagic response to cancer cells, ***Eur J Med Chem***, 188 (2020) 112011. **(JIF:4.5)**

15. R. Tiwari, N. Manzar, V. Bhatia, A. Yadav, M.A. Nengroo, **D. Datta**, S. Carskadon, N. Gupta, M. Sigouros, F. Khani, M. Poutanen, A. Zoubeidi, H. Beltran, N. Palanisamy, B. Ateeq, Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer, ***Nat Commun***, 11 (2020) 384. **(JIF:17.69)**

16. A. Shukla, R. Tyagi, S. Meena, **D. Datta**, S.K. Srivastava, F. Khan, 2D- and 3D-QSAR modelling, molecular docking and in vitro evaluation studies on 18beta-glycyrrhetinic acid derivatives against triple-negative breast cancer cell line, ***J Biomol Struct Dyn***, 38 (2020) 168-185. **(JIF:4.4)**

17. M. Riyazuddin, A. Husain, G.R. Valicherla, S. Verma, A.P. Gupta, K.S. Praveena, A. Singh, S.R. Avula, K.V. Sashidhara, **D. Datta**, J.R. Gayen, Development and validation of LC-MS/MS method for quantification of novel PP2A - beta-catenin signalling inhibitor, S011-2111 in mice plasma: Application to its preclinical pharmacokinetic studies, ***J Chromatogr B Analyt Technol Biomed Life Sci***, 1130-1131 (2019) 121829. **(JIF:3.2)**

18. J. Gour, S. Gatadi, R. Akunuri, M.V. Yaddanapudi, M.A. Nengroo, **D. Datta**, S. Chopra, S. Nanduri, Catalyst-free facile synthesis of polycyclic indole/pyrrole substituted-1,2,3-triazoles, ***Org Biomol Chem***, 17 (2019) 8153-8165. **(JIF:3.2)**

19. P. Pandey, D. Singh, M. Hasanain, R. Ashraf, M. Maheshwari, K. Choyal, A. Singh, **D. Datta**, B. Kumar, J. Sarkar, 7-hydroxyfrullanolide, isolated from Sphaeranthus indicus, inhibits colorectal cancer cell growth by p53-dependent and -independent mechanism, ***Carcinogenesis***, 40 (2019) 791-804. **(JIF:4.7)**

20. V.K. Pawar, Y. Singh, K. Sharma, A. Shrivastav, A. Sharma, A. Singh, J.G. Meher, P. Singh, K. Raval, A. Kumar, H.K. Bora, **D. Datta**, J. Lal, M.K. Chourasia, Improved chemotherapy against breast cancer through immunotherapeutic activity of fucoidan decorated electrostatically assembled nanoparticles bearing doxorubicin, ***Int J Biol Macromol***, 122 (2019) 1100-1114. **(JIF:8.2)**

21. H.S. Cheruvu, N.K. Yadav, G.R. Valicherla, R.K. Arya, Z. Hussain, C. Sharma, K.R. Arya, R.K. Singh, **D. Datta**, J.R. Gayen, LC-MS/MS method for the simultaneous quantification of luteolin, wedelolactone and apigenin in mice plasma using hansen solubility parameters for liquid-liquid extraction: Application to pharmacokinetics of Eclipta alba chloroform fraction, ***J Chromatogr B Analyt Technol Biomed Life Sci,*** 1081-1082 (2018) 76-86. **(JIF:3.2)**

22. N. Sahu, S. Meena, V. Shukla, P. Chaturvedi, B. Kumar, **D. Datta**, K.R. Arya, Extraction, fractionation and re-fractionation of Artemisia nilagirica for anticancer activity and HPLC-ESI-QTOF-MS/MS determination, ***J Ethnopharmacol***, 213 (2018) 72-80. **(JIF:5.4)**

23. A. Bhattacharjee, M. Hasanain, M. Kathuria, A. Singh, **D. Datta**, J. Sarkar, K. Mitra, Ormeloxifene-induced unfolded protein response contributes to autophagy-associated apoptosis via disruption of Akt/mTOR and activation of JNK, ***Sci Rep***, 8 (2018) 2303. **(JIF:4.99)**

24. B.L. Hopkins, M. Nadler, J.J. Skoko, T. Bertomeu, A. Pelosi, P.M. Shafaei, K. Levine, A. Schempf, B. Pennarun, B. Yang, **D. Datta**, O. Bucur, K. Ndebele, S. Oesterreich, D. Yang, M. Giulia Rizzo, R. Khosravi-Far, C.A. Neumann, A Peroxidase Peroxiredoxin 1-Specific Redox Regulation of the Novel FOXO3 microRNA Target let-7, ***Antioxid Redox Signal***, 28 (2018) 62-77. **(JIF:6.6)**

25. M.K. Hussain, D.K. Singh, A. Singh, M. Asad, M.I. Ansari, M. Shameem, S. Krishna, G.R. Valicherla, V. Makadia, S. Meena, A.L. Deshmukh, J.R. Gayen, M. Imran Siddiqi, **D. Datta***, K. Hajela*, D. Banerjee*, A Novel Benzocoumarin-Stilbene Hybrid as a DNA ligase I inhibitor with in vitro and in vivo anti-tumor activity in breast cancer models, ***Sci Rep***, 7 (2017) 10715. **(JIF:4.99)**

26. V.K. Pawar, Y. Singh, K. Sharma, A. Shrivastav, A. Sharma, A. Singh, J.G. Meher, P. Singh, K. Raval, H.K. Bora, **D. Datta**, J. Lal, M.K. Chourasia, Doxorubicin Hydrochloride Loaded Zymosan-Polyethylenimine Biopolymeric Nanoparticles for Dual 'Chemoimmunotherapeutic' Intervention in Breast Cancer, ***Pharm Res***, 34 (2017) 1857-1871. **(JIF:3.7)**

27. S. Maheshwari, S.R. Avula, A. Singh, L.R. Singh, G.R. Palnati, R.K. Arya, S.H. Cheruvu, S. Shahi, T. Sharma, S. Meena, A.K. Singh, R. Kant, M. Riyazuddin, H.K. Bora, M.I. Siddiqi, J.R. Gayen, K.V. Sashidhara, **D. Datta***, Discovery of a Novel Small-Molecule Inhibitor that Targets PP2A-beta-Catenin Signaling and Restricts Tumor Growth and Metastasis, ***Mol Cancer Ther,*** 16 (2017) 1791-1805. **(JIF:6.0)**

28. N.K. Yadav, R.K. Arya, K. Dev, C. Sharma, Z. Hossain, S. Meena, K.R. Arya, J.R. Gayen, **D. Datta***, R.K. Singh*, Alcoholic Extract of Eclipta alba Shows In Vitro Antioxidant and Anticancer Activity without Exhibiting Toxicological Effects, ***Oxid Med Cell Longev***, 2017 (2017) 9094641. **(JIF:7.3)**

29. A.P. Oluyori, A.K. Shaw, G.A. Olatunji, P. Rastogi, S. Meena, **D. Datta**, A. Arora, S. Reddy, S. Puli, Sweet Potato Peels and Cancer Prevention, ***Nutr Cancer***, 68 (2016) 1330-1337. **(JIF:2.9)**

30. A.K. Singh, S.S. Chauhan, S.K. Singh, V.V. Verma, A. Singh, R.K. Arya, S. Maheshwari, M.S. Akhtar, J. Sarkar, V.M. Rangnekar, P.M.S. Chauhan, **D. Datta***, Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer, ***Carcinogenesis***, 37 (2016) 1027-1040. **(JIF:4.7)**

31. M. Yadav, A.K. Singh, H. Kumar, G. Rao, B. Chakravarti, A. Gurjar, S. Dogra, S. Kushwaha, A.L. Vishwakarma, P.N. Yadav, **D. Datta**, A.K. Tripathi, N. Chattopadhyay, A.K. Trivedi, S. Sanyal, Epidermal growth factor receptor inhibitor cancer drug gefitinib modulates cell growth and differentiation of acute myeloid leukemia cells via histamine receptors, ***Biochim Biophys Acta***, 1860 (2016) 2178-2190. **(JIF:3.0)**

32. A.K. Jha, S. Umar, R.K. Arya, **D. Datta**, A. Goel, Pyrano[3,2-c]julolidin-2-ones: a novel class of fluorescent probes for ratiometric detection and imaging of Hg(2+) in live cancer cells, ***J Mater Chem B***, 4 (2016) 4934-4940. **(JIF:7.0)**

33. T. Mishra, R.K. Arya, S. Meena, P. Joshi, M. Pal*, B. Meena, D.K. Upreti, T.S. Rana, **D. Datta***, Isolation, Characterization and Anticancer Potential of Cytotoxic Triterpenes from Betula utilis Bark, ***PLoS One***, 11 (2016) e0159430. **(JIF:3.7)**

34. S. Faes, A. Planche, E. Uldry, T. Santoro, C. Pythoud, J.C. Stehle, J. Horlbeck, I. Letovanec, N. Riggi, **D. Datta**, N. Demartines, O. Dormond, Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors, ***Oncotarget***, 7 (2016) 36666-36680. **(JIF:5.1)**

35. G.R. Valicherla, K.M. Dave, A.A. Syed, M. Riyazuddin, A.P. Gupta, A. Singh, Wahajuddin, K. Mitra, **D. Datta**, J.R. Gayen, Formulation optimization of Docetaxel loaded self-emulsifying drug delivery system to enhance bioavailability and anti-tumor activity, ***Sci Rep***, 6 (2016) 26895. **(JIF:4.99)**

36. T. Mishra, M. Pal, S. Meena, **D. Datta**, P. Dixit, A. Kumar, B. Meena, T.S. Rana, D.K. Upreti, Composition and in vitro cytotoxic activities of essential oil of Hedychium spicatum from different geographical regions of western Himalaya by principal components analysis, ***Nat Prod Res***, 30 (2016) 1224-1227. **(JIF:2.2)**

37. R.K. Arya, A. Singh, N.K. Yadav, S.H. Cheruvu, Z. Hossain, S. Meena, S. Maheshwari, A.K. Singh, U. Shahab, C. Sharma, K. Singh, T. Narender, K. Mitra, K.R. Arya, R.K. Singh, J.R. Gayen, **Datta***, Anti-breast tumor activity of Eclipta extract in-vitro and in-vivo: novel evidence of endoplasmic reticulum specific localization of Hsp60 during apoptosis, ***Sci Rep***, 5 (2015) 18457. **(JIF:4.99)**

38. S. Kundooru, P. Das, S. Meena, V. Kumar, M.I. Siddiqi, **D. Datta**, A.K. Shaw, Substrate and stereocontrolled iodocycloetherification of highly functionalized enantiomerically pure allylic alcohols: application to synthesis of cytotoxic 2-epi jaspine B and its biological evaluation, ***Org Biomol Chem,*** 13 (2015) 8241-8250. **(JIF:3.2)**

39. A.K. Singh, R.K. Arya, S. Maheshwari, A. Singh, S. Meena, P. Pandey, O. Dormond, **Datta***, Tumor heterogeneity and cancer stem cell paradigm: updates in concept, controversies and clinical relevance, ***Int J Cancer***, 136 (2015) 1991-2000. **(JIF:6.4)**

40. V.K. Pawar, S.B. Panchal, Y. Singh, J.G. Meher, K. Sharma, P. Singh, H.K. Bora, A. Singh, **D. Datta**, M.K. Chourasia, Immunotherapeutic vitamin E nanoemulsion synergies the antiproliferative activity of paclitaxel in breast cancer cells via modulating Th1 and Th2 immune response, ***J Control Release,*** 196 (2014) 295-306. **(JIF:10.8)**

41. B. Chakravarti, T. Akhtar, B. Rai, M. Yadav, J. Akhtar Siddiqui, S.K. Dhar Dwivedi, R. Thakur, A.K. Singh, A.K. Singh, H. Kumar, K. Khan, S. Pal, S.K. Rath, J. Lal, R. Konwar, A.K. Trivedi, **D. Datta**, D.P. Mishra, M.M. Godbole, S. Sanyal, N. Chattopadhyay, A. Kumar, Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents, ***J Med Chem***, 57 (2014) 8010-8025. **(JIF:8.0)**

42. S.S. Chauhan, A.K. Singh, S. Meena, M. Lohani, A. Singh, R.K. Arya, S.H. Cheruvu, J. Sarkar, J.R. Gayen, **D. Datta**, P.M. Chauhan, Synthesis of novel beta-carboline based chalcones with high cytotoxic activity against breast cancer cells, ***Bioorg Med Chem Lett***, 24 (2014) 2820-2824. **(JIF:2.9)**

43. S. Krishna, D.K. Singh, S. Meena, **D. Datta**, M.I. Siddiqi, D. Banerjee, Pharmacophore-based screening and identification of novel human ligase I inhibitors with potential anticancer activity, ***J Chem Inf Model,*** 54 (2014) 781-792. **(JIF:5.6)**

44. J.K. Kanaujiya, S. Lochab, I. Kapoor, P. Pal, **D. Datta**, M.L. Bhatt, S. Sanyal, G. Behre, A.K. Trivedi, Proteomic identification of Profilin1 as a corepressor of estrogen receptor alpha in MCF7 breast cancer cells, ***Proteomics***, 13 (2013) 2100-2112. **(JIF:3.4)**

45. A.K. Singh, R.K. Arya, A.K. Trivedi, S. Sanyal, R. Baral, O. Dormond, D.M. Briscoe, **Datta***, Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12, ***Cytokine Growth Factor Rev***, 24 (2013) 41-49. **(JIF:13.0)**

46. A. Basu, T. Liu, P. Banerjee, E. Flynn, D. Zurakowski, **D. Datta**, O. Viklicky, M. Gasser, A.M. Waaga-Gasser, J. Yang, S. Pal, Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression, ***Cancer Lett***, 321 (2012) 179-186. **(JIF:9.7)**

47. G.M. McMahon, **D. Datta**, S. Bruneau, M. Kann, M. Khalid, J. Ho, T. Seto, J.A. Kreidberg, I.E. Stillman, D.M. Briscoe, Constitutive activation of the mTOR signaling pathway within the normal glomerulus, ***Biochem Biophys Res Commun***, 425 (2012) 244-249. **(JIF:3.1)**

48. S. Bruneau[#], D. Datta[#], J.A. Flaxenburg, S. Pal, D.M. Briscoe, TRAF6 inhibits proangiogenic signals in endothelial cells and regulates the expression of vascular endothelial growth factor, ***Biochem Biophys Res Commun***, 419 (2012) 66-71. ([#]Equal Contribution) **(JIF:3.1)**

49. P. Banerjee, A. Basu, **D. Datta**, M. Gasser, A.M. Waaga-Gasser, S. Pal, The heme oxygenase-1 protein is overexpressed in human renal cancer cells following activation of the Ras-Raf-ERK pathway and mediates anti-apoptotic signal, ***J Biol Chem***, 286 (2011) 33580-33590. **(JIF:4.8)**

50. A. Hoerning, K. Koss, **D. Datta**, L. Boneschansker, C.N. Jones, I.Y. Wong, D. Irimia, K. Calzadilla, F. Benitez, P.F. Hoyer, W.E. Harmon, D.M. Briscoe, Subsets of human CD4(+) regulatory T cells express the peripheral homing receptor CXCR3, ***Eur J Immunol***, 41 (2011) 2291-2302. **(JIF:5.4)**

51. **D. Datta**, P. Banerjee, M. Gasser, A.M. Waaga-Gasser, S. Pal, CXCR3-B can mediate growth-inhibitory signals in human renal cancer cells by down-regulating the expression of heme oxygenase-1, ***J Biol Chem***, 285 (2010) 36842-36848. **(JIF:4.8)**

52. M. Edelbauer, **D. Datta**, I.H. Vos, A. Basu, M.P. Stack, M.E. Reinders, M. Sho, K. Calzadilla, P. Ganz, D.M. Briscoe, Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo, ***Blood***, 116 (2010) 1980-1989. **(JIF:20.3)**

53. A. Basu, D. **Datta, D**. Zurakowski, S. Pal, Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development, ***J Biol Chem***, 285 (2010) 25196-25202. **(JIF:4.8)**

54. A. Basu, A. Hoerning, **D. Datta**, M. Edelbauer, M.P. Stack, K. Calzadilla, S. Pal, D.M. Briscoe, Cutting edge: Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production, ***J Immunol***, 184 (2010) 545-549. **(JIF:4.4)**

55. **D. Datta**, A.G. Contreras, A. Basu, O. Dormond, E. Flynn, D.M. Briscoe, S. Pal, Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells, ***Cancer Res***, 69 (2009) 8902-8909. **(JIF:13.64)**

56. O. Dormond, A.G. Contreras, E. Meijer, **D. Datta**, E. Flynn, S. Pal, D.M. Briscoe, CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo, ***J Immunol***, 181 (2008) 8088-8095. **(JIF:4.4)**

57. **D. Datta**, A.G. Contreras, M. Grimm, A.M. Waaga-Gasser, D.M. Briscoe, S. Pal, Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression, ***J Am Soc Nephrol***, 19 (2008) 2437-2446. **(JIF:13.6)**

58. A. Basu, A.G. Contreras, **D. Datta**, E. Flynn, L. Zeng, H.T. Cohen, D.M. Briscoe, S. Pal, Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer, ***Cancer Res***, 68 (2008) 5689-5698. **(JIF:13.64)**

59. **D. Datta**, O. Dormond, A. Basu, D.M. Briscoe, S. Pal, Heme oxygenase-1 modulates the expression of the anti-angiogenic chemokine CXCL-10 in renal tubular epithelial cells, ***Am J Physiol Renal Physiol,*** 293 (2007) F1222-1230. **(JIF:4.2)**

60. **D. Datta**, J.A. Flaxenburg, S. Laxmanan, C. Geehan, M. Grimm, A.M. Waaga-Gasser, D.M. Briscoe, S. Pal, Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer, ***Cancer Res***, 66 (2006) 9509-9518. **(JIF:13.64)**

61. S. Laxmanan, **D. Datta**, C. Geehan, D.M. Briscoe, S. Pal, CD40: a mediator of pro- and anti-inflammatory signals in renal tubular epithelial cells, ***J Am Soc Nephrol***, 16 (2005) 2714-2723. **(JIF:13.6)**

Complete List of Filed Patents:

Sl No.	Title	Country	Filed on (Date)	Role and Names of other inventors
1	Title: SMAC MIMETICS FOR TREATMENT OF CANCER, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF, ***IND studies are on-going, will move for clinical trial soon***	Filing Country: India and Outside India, Filing Date: International Application No. PCT/IN2021 /051182,	17 December 2021	**Role: Principal Investigator or Applicant** Haq W, Ali R, Singh A, Nengroo MA, Katekar R, Singh G, Vaishnav J, Afsar M, Singh M, Rath SK, Koley D, Mishra DP, Ramachandran R, Ampapathi RS, Gayen JR, **Datta D.**
2	Synthesis of 6/8((di(hetero-2-ylmethyl)amino)methyl)-7-hydroxyl-4-(methylthio)-2-oxo-2H- chromene-3-carbonotriles and uses thereof	Indian Patent Filed-0267NF2015 3988DEL2015	08-Dec-15	**Role: Major Contributor** Goel A, Jha AK, Raghuvanshi R, Arya RK, **Datta D.**
3	Semicarbazone based chalcones as potent anticancer agents.	Indian Patent Filed-0065NF2014 3716DEL2014	16-Dec-2014	**Role: Major Contributor** Sashidhara KV, **Datta D,** Gayen JR, Avula SR, Singh A, Cheruvu SH, Singh R, Palnati GR, Maheshwari S, Arya RK, and Singh AK.

4	New Rapamycin conjugates and process for preparation	Indian Patent Filed-0236NF2014 2865DEL2014	08-Oct-14	**Role: Major Contributor** Haq W, Ali R, **Datta D** and Arya RK.
5	Aryl naphthyl methanone oxime (s) and process for preparation thereof	US Patent App. 14/915,194	30-Aug-2013	**Role: Minor Contributor** S Sanyal, A Kumar, N Chattopadhyay, J Lal, AK Trivedi, **D Datta,** SK Rath, et al.

Complete list of published book chapters, monographs:

S.No	Title	Author's Name	Publisher	Year of Publication
1.	Chapter Title: Epigenetic Impact of Stem Cell Toxicants	Singh AK, Singh A, Arya RK, Yadav N, Datta D*. **(*Communicating Author)**	Royal Society of Chemistry	2016
2.	Chapter Title: Tumor microenvironment and Cancer Stem cells: Therapeutic potential of Epigenetic Inhibitors. Book Name: 'Rediscovering Cancer: From Mechanism to Therapy'	Singh AK, Chaturvedi P, Datta D*. **(*Communicating Author)**	Apple Academic Press, USA.	2018
3	Chapter Title: Iron Vulnerability of Cancer Stem Cells: Role of ROS and Beyond	Nengroo MA, Sinha A, Datta D*. **(*Communicating Author)**	Springer Nature, USA	2021
4	Chapter Title: Modulation of DNA/RNA Methylation by Small-Molecule Modulators and Their Implications in Cancer	Verma A, Sinha A, Datta D*. **(*Communicating Author)**	Springer Nature, USA	2022

EMR Funding Details:

Sl. No	Title of the project	Project Type/ Category	Budget	Govt./ Industry	Tenure	Current Status
1	PAN CSIR CANCER RESEARCH PROGRAM MAKING CANCER CARE AFFORDABLE Empowering Women's Health: Focusing on Breast and Gynaecological Cancers of Indian Relevance	**CSIR-HQ** HCP-40	48.5 Crores	CSIR	2021-26	On-going
2	Harnessing therapeutic potential of Novel Spisulosine derivative as robust autophagy inducer against Triple Negative Breast Cancer (TNBC) in-vitro and in-vivo.	**ICMR-EMR** 2019-1350	19.5 Lakhs	ICMR	2019-22	Completed

3	Targeting Triple Negative Breast Cancer (TNBC) by a plant derived small molecule: An in-vitro and in-vivo approach	**DST: SERB** EMR/2016/006935	36.5 Lakhs	DST	2018-21	Completed
4	Development of Novel Small Molecule SMAC Mimetics as Cancer Therapeutics	**DBT-BIRAC** BT/AIR0568/PACE-15/18	46.5 Lakhs	DBT	2019-21	Completed

Honors/Awards:

Invited Speaker, RGCB Research Conference, 2023, Trivandrum, India
Invited Speaker, Aurigene Oncology Limited, 2023, Bangalore, India
Invited Speaker, Society for Biological Chemists (SBC) Meeting, 2022, SNU, Kolkata, India
Invited Speaker, International Conference on CDCT, 2018, IITR, Lucknow, India
Invited Speaker, Society for Biological Chemists (SBC) Meeting, 2017, JNU, New Delhi, India
Young Investigator Award, 2010, American Transplant Congress, San Diego, CA, USA
Young Investigator Award, 2007, American Transplant Congress, San Diego, CA, USA
1st. Class 1st. Award in BS in Biology, Burdwan University, West Bengal, India

Contribution to National/International issues:

1. Reviewer of CSIR, DBT, DST, ICMR EMR grant applications

2. Serve as an ad-hoc reviewer for peer reviewed international journals like Journal of Clinical Investigation, Oncogene, Cancer Letters, BBA etc.